Biogen
Headquarters in Cambridge, Massachusetts | |
| Formerly | Biogen Idec Inc. (2003–2015) |
|---|---|
| Company type | Public |
| Industry | Biotechnology |
| Founded | 1978 |
| Founders | |
| Headquarters | Cambridge, Massachusetts, U.S. |
Key people |
|
| Products | |
| Revenue | US$9.676 billion (2024) |
| US$1.906 billion (2024) | |
| US$1.632 billion (2024) | |
| Total assets | US$28.05 billion (2024) |
| Total equity | US$16.72 billion (2024) |
Number of employees | 7,605 (2024) |
| Website | biogen |
| Footnotes / references | |
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.